Videos

Closing thoughts on unmet needs in the multiple myeloma space, particularly disparities in the care of patients with MM of racial and ethnic minorities.

Dr. Cook and Dr. Pianko share their perspectives on optimizing treatment strategies for individual patients in order to maximize response and mitigate adverse events.

Moshe Ornstein, MD, explains how he selects a frontline IO/TKI combination regimen for a patient with advanced renal cell carcinoma.

Dr Brian Rini shares his view on the data comparing IO/TKI and IO/IO combination regimens for the treatment of advanced renal cell carcinoma.

A better understanding of tumor biology may be necessary for identifying novel non-immunotherapy–based therapeutic strategies for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Probiotics and other agents targeting fatty acid oxidation are also under evaluation as treatment options for patients with renal cell carcinoma, according to Rana R. McKay, MD.

Defining transplant eligibility, explaining the role of transplant in NDMM, and differentiating between high- and low-risk MM.

Thoughtful discussion centered around recently presented updates to the GRIFFIN, MASTER, and GMMG-CONCEPT studies in NDMM patients.

Panelists reflect on the evolving landscape of BCMA targeting bispecifics and how additional agents will impact the management of multiple myeloma.

Centering focus on the first-line treatment armamentarium, key opinion leaders consider factors that aid in the selection of best therapy for patients with advanced bladder cancer.

A brief discussion on supportive care available to patients with bladder cancer and the role it plays within the treatment pathway.

Key opinion leaders consider when it is appropriate to utilize bispecific dose holds or reductions when treating patients with multiple myeloma.

Other angiogenic agents are also under investigation in renal cell carcinoma, according to Rana McKay, MD, who indicates it will be interesting to see how they compare with belzutifan.

The panel highlights remaining unmet needs in the management of multiple myeloma and speculates on the future of treatment.

Noffar Bar, MD, shares how she would choose between the potential bispecific antibodies for treatment of multiple myeloma after recent data updates.

Expert perspectives on clinical trial data and personal experience with amivantamab in the setting of EGFR Exon20+ non–small cell lung cancer.

Key opinion leaders in non–small cell lung cancer management reflect on the current first- and second-line treatment options available to patients with EGFR Exon20+ disease.

A Matching-Adjusted Indirect Comparison of Acalabrutinib Versus Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia

Medical oncologists who specialize in gastrointestinal cancers offer clinical insights on monitoring patients following treatment with adjuvant chemotherapy.

Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.

The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.

Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.

Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.

A comprehensive discussion on treatment decision-making for patients with colorectal cancer following the IDEA collaboration analysis.

Shared insight from a panel of experts on the current state of cytogenetics in myelofibrosis and how it impacts treatment pathways for patients.

Expert panelists provide an overview of the signs and symptoms indicative of myelofibrosis and consider factors that help to inform prognostication.

Eunice S. Wang, MD, shares first-line treatment approaches for patients with NPM1-mutant AML, discussing current clinical data.

The panel discuss the need for personalized treatment approaches for young, fit patients with newly diagnosed acute myeloid leukemia, as well as when transplant should be considered.

Clinical pearls for community oncologists concerning the real-world application of existing treatments while considering feasibility, cost, and ease of care.

Conversation centered around patient frailty, Dr. Cook and Dr. Pianko emphasize the importance of accurately assessing frailty and adjusting treatment plans accordingly.